Clinical trial NCT05105048: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
Official title: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 When Administered to Healthy Japanese Adults (18-40 Years of Age) in the United States
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cytomegalovirus Infection
Keywords: Moderna
mRNA-1647
Cytomegalovirus
CMV
Cytomegalovirus Vaccine
Cytomegalovirus Infections
Cytomegalovirus Congenital
Virus Diseases
Infection Viral
Messenger RNA
Lead sponsor: ModernaTX, Inc.
Sponsor class: INDUSTRY
First posted: 2021-11-03
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The main objective of this study is to evaluate the safety, reactogenicity, and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive Japanese adults 18 to 40 years of age in the United States.


Eligibility criteria: Inclusion Criteria:

* Participant is a Japanese Adult 18-40 years of age at the time of consent who, in the opinion of the investigator, is in good health based on review of medical history and screening physical examination. Japanese participants are defined as individuals born in Japan, with both parents and 4 grandparents who were born in Japan, and who have not lived outside of Japan for more than 10 years in total.
* For the CMV-seronegative groups: Participant is serum CMV IgG negative/ IgM negative.
* For the CMV-seropositive groups: Participant is either serum CMV IgG positive/IgM negative or IgG positive/IgM positive.
* Participant has a body mass index (BMI) from ≥18 kilograms (kg)/square meter (m\^2) to ≤35 kg/m\^2, inclusive.

Exclusion Criteria:

* History of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. Clinically unstable is defined as a diagnosis or condition requiring significant changes in management or medication within the 2 months prior to screening and includes ongoing workup of an undiagnosed illness that could lead to a new diagnosis or condition.
* Participant has elevated liver function tests, defined as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP), or elevated creatinine or reduced platelets, with a toxicity score of Grade ≥1 at screening.
* Participant has laboratory test results (hematology, chemistry, and coagulation) with a toxicity score of Grade ≥1 at screening.
* Received or plans to receive any non-study vaccine \<28 days prior to any study injection; in addition, the following criteria for COVID-19 and influenza vaccines apply:

  i. Any COVID-19 vaccination series must have been completed a minimum of 28 days prior to receiving any dose of the study injection.

ii. COVID-19 vaccines (regardless of manufacturer) must be administered at least 28 days prior to or after any study injection.

iii. Influenza vaccines may be administered \>14 days prior to or after any study injection.

* Participant has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months before the day of first injection (Day 1) (for corticosteroids, \>5 mg/day of prednisone equivalent) or plans to do so during the course of the study. Inhaled, nasal, and topical steroids are allowed.
* Participant has received an antiviral with activity against CMV (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, acyclovir, valacyclovir) within 2 weeks before the first injection or plans to do so during the course of the study.
* Participant received any investigational CMV vaccine.
* History of myocarditis, pericarditis, or myopericarditis.
* Reported medical history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); or a positive screening test for hepatitis B surface antigen (HbSAg), hepatitis C antibodies, or HIV 1 or 2 antibodies.

Other inclusion and exclusion criteria may apply.

Primary outcomes:
measure: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
timeFrame: Up to Day 176 (7 days after each injection)
measure: Number of Participants With Unsolicited Adverse Events (AEs)
timeFrame: Up to Day 197 (28 days after each injection)
measure: Number of Participants With Medically-Attended AEs (MAAEs)
timeFrame: Day 1 through 6 months after the last injection (up to Day 347)
measure: Number of Participants With Serious AEs (SAEs)
timeFrame: Day 1 through End of Study (EOS) (up to Day 347)
measure: Number of Participants With AEs of Special Interest (AESIs)
timeFrame: Day 1 through EOS (up to Day 347)
Secondary outcomes:
measure: Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies (nAbs) Against Epithelial Cell Infection and Against Fibroblast Infection
timeFrame: Days 1, 29, 85, 169, 197, and 347
measure: Geometric Mean Fold-Rise (GMFR) of nAb Against Epithelial Cell Infection and Against Fibroblast Infection
timeFrame: Days 29, 85, 169, 197, and 347
measure: Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases in nAb over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection
timeFrame: Days 29, 85, 169, 197, and 347
measure: GMT of Anti-Glycoprotein B (gB) Specific Immunoglobulin G (IgG) and Anti-Pentamer Specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA)
timeFrame: Days 1, 29, 85, 169, 197, and 347
measure: GMFR of Anti-gB and Anti-Pentamer Specific IgG
timeFrame: Days 29, 85, 169, 197, and 347
measure: Proportion of Participants with ≥2-Fold, 3-Fold, and 4-Fold Increases Over Baseline in Anti-gB and Anti-Pentamer Specific IgG
timeFrame: Days 29, 85, 169, 197, and 347
Other outcomes:
Locations:
city: North Hollywood
country: United States
facility: Velocity Clinical Research
state: California
city: San Diego
country: United States
facility: California Research Foundation
state: California
city: Honolulu
country: United States
facility: East-West Medical Research Institute
state: Hawaii
Study officials:
References: